NASDAQ$RNA

Atrium Therapeutics Inc · Q3 2021 earnings

Q3 2021 earnings ·

Headline financials

Total Revenue

$2.16M

Previous: $1.75M+23.9%
Capital Expenditures

-$2.03M

Previous: -$855K-137.8%
Free Cash Flow

-$31.3M

Previous: -$12.3M-154.7%
Net Income

-$29.3M

Previous: -$11.4M-155.9%
Operating Income

-$29.3M

Previous: -$11.5M-155.4%
Gross Profit

$0.00

No prior period

Revenue & EPS history

Atrium Therapeutics Inc · Revenue · Quarterly

$2.16M

Q3 2021+23.9%vs Q3 2020
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Revenue by segment

Atrium Therapeutics Inc · $19.6M total across 1 segment · Q1 2026

  • Reportable Segment
    $19.6M—

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro